| Year |
Citation |
Score |
| 2020 |
Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, ... ... Mukherjee S, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of Urology. 101097JU000000000000. PMID 31899651 DOI: 10.1097/Ju.0000000000000714 |
0.391 |
|
| 2019 |
Kapoor A, Wong NC, Wang Y, Mukherjee S, Hotte S, Dayes I, Lukka H. Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology. PMID 31535625 DOI: 10.4103/aja.aja_66_19 |
0.374 |
|
| 2019 |
Donovan E, Dhesy-Thind S, Mukherjee S, Kucharczyk M, Swaminath A. Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists. The Breast Journal. PMID 31264272 DOI: 10.1111/tbj.13435 |
0.369 |
|
| 2019 |
Mackett K, Dhesy-Thind S, Donovan EK, Mukherjee S, Swaminath A, Leong DP, Voruganti S, Sussman J, Wright J, Okawara G, Fraser G, Sagar S, Bordeleau L, Ellis PM, Hirte H, et al. A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta; International Journal of Clinical Chemistry. PMID 31054914 DOI: 10.1016/J.Cca.2019.04.083 |
0.352 |
|
| 2012 |
Major P, Lacombe L, Fradet Y, Foley R, Scheid E, Bergeron A, Mukherjee S, Finn OJ, Gariepy J, Sekaly RP, Hotte S, Chou S. Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients Cancer Research. 72: A16-A16. DOI: 10.1158/1538-7445.PRCA2012-A16 |
0.33 |
|
| 2008 |
Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. The Cochrane Database of Systematic Reviews. CD005390. PMID 18646127 DOI: 10.1002/14651858.CD005390.pub2 |
0.329 |
|
| Show low-probability matches. |